In a nutshell
This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients.
A high number of patients with acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL) experience relapse (worsening of the disease) or are refractory (not responsive) to standard treatments.
Inotuzumab ozogamicin (INO) is an immunotherapy already approved for the treatment of relapsed/refractory (r/r) ALL. However, there are few studies focusing on the effectiveness and safety of INO in patients with r/r ALL and r/r NHL.
Methods & findings
This study investigated 12 studies on INO in patients with r/r ALL and NHL. It involved 644 patients overall. They were divided into two groups. 471 patients had r/r ALL and 173 patients had r/r NHL.
The overall complete remission (CR; no signs of cancer) rate was 67% for patients with ALL. 45% of patients with ALL had a minimum residual disease (MRD; a small number of cancer cells left after treatment) response.
In patients with NHL the CR rate was 28%.
The most common side effects were low platelet (blood cells involved in clotting) counts (48%) and low white blood cell counts (29%).
The bottom line
This study concluded that INO was effective for the treatment of r/r ALL and NHL with manageable side effects.
The fine print
The number of studies included in the analysis was very low. The dose of INO was different in a couple of studies.
Published By :
Clinical lymphoma, myeloma & leukemia
Mar 01, 2021